Table 6.
Unadjusted and adjusted analyses for the risk of NAFLD in premenopausal women.
| Unadjusted OR (95% CI) | P | Adjusted OR (95% CI) | P | |
|---|---|---|---|---|
| Age | 1.03 (0.99–1.06) | 0.124 | 1.04 (0.99–1.10) | 0.121 |
| Hypertension | 2.68 (1.73–4.17) | <0.001 | 1.57 (0.69–3.55) | 0.283 |
| Diabetes | 3.57 (2.22–5.74) | <0.001 | 2.07 (0.77–5.53) | 0.149 |
| Triglyceridemia | 5.57 (3.09–10.03) | <0.001 | 1.75 (0.62–5.00) | 0.293 |
| HDL | 0.46 (0.29–0.75) | 0.002 | 0.36 (0.16–0.83) | 0.016 |
| Central obesity | 4.91 (3.10–7.76) | <0.001 | 2.79 (1.25–6.24) | 0.012 |
| Smoking | 0.78 (0.21–2.89) | 0.713 | 0.70 (0.08–6.14) | 0.744 |
| Exercise | 1.59 (0.96–2.62) | 0.072 | 1.70 (0.79–3.66) | 0.176 |
| ALT | 1.07 (1.04–1.10) | <0.001 | 1.06 (1.02–1.10) | 0.003 |
| GGT | 1.01 (1.00–1.02) | 0.022 | 1.01 (0.99–1.03) | 0.475 |
| HOMA | 1.72 (1.37–2.16) | <0.001 | 2.46 (1.51–4.00) | <0.001 |
NAFLD: nonalcoholic fatty liver disease; ALT: alanine aminotransferase; GGT: gamma-glutamyl transpeptidase; OR: odds ratio; CI: confidence interval; HDL: high density lipoprotein; HOMA: homeostasis model assessment-estimated insulin resistance.